Prevention of chemotherapy-induced alopecia using an effective scalp cooling system
Introduction
Alopecia is one of the most unwelcome side-effects of chemotherapy. Although not life-threatening, it can be psychologically devastating and can even lead some patients to reject potentially curative treatment.
The degree of alopecia varies amongst different drugs. Chemotherapeutic agents such as the taxanes (TX), anthracyclines (ANR) and etoposide (ET) have been shown to have significant antitumour activity in solid tumours either alone or in combination regimes 1, 2, 3, 4, 5, 6. These drugs are also associated with significant alopecia as one of their main side-effects. The percentage of patients experiencing alopecia associated with the use of anthracyclines or taxanes is over 70% in most studies, whilst similar results have been reported for etoposide 7, 8, 9, 10, 11. Alopecia induced by these agents is dose dependent, whilst its severity also depends on the combination of other cytotoxic agents 3, 12.
A variety of different methods have been used for the prevention of chemotherapy-induced alopecia. These include scalp tourniquets, scalp cooling systems and immunomodulator techniques 13, 14, 15, 16.
The cooling systems are based on the theory that by cooling the scalp, vasoconstriction is produced, which reduces the amount of drug delivered to the hair follicles. Cellular uptake by the hair follicle, which occurs more readily at warmer temperatures, is also reduced [17]. Several techniques have been used: bags with crushed ice, packs or caps containing cryogel and caps connected to a cooling device. Hair preservation is achieved in many cases, although studies showing failure of hair loss prevention have also been reported 18, 19, 20. Recent studies have shown that the efficacy of a scalp cooling system is inversely associated with epi- and subcutaneous scalp temperatures 17, 21. Based on these findings, pre- and postchemotherapy scalp-cooling has been utilised in order to maintain steady, low scalp temperatures. Encouraging results have been reported in small studies, using anthracycline-containing regimes 17, 18, 22.
The Penguin Cold Cap system™ is a scalp cooling system, which is based on previous research findings. The aim of this study was to evaluate the applicability and efficacy of this new cooling system in patients receiving various chemotherapeutic regimes that are frequently associated with significant alopecia.
Section snippets
Patients and methods
The Penguin Cold Cap system™ was studied in patients who received chemotherapy regimes containing at least one drug from three main alopecia-causing drug groups: taxanes (TX), anthracyclines (ANR) or etoposide (ET). No previous chemotherapy or brain radiotherapy was allowed. The method was approved by our Ethics Committee. The system was provided by MSC Hellas A.E.
The above cold cap system offers protection from hair loss by maintaining scalp temperatures below 15°C before, during and after
Results
70 patients entered the study. Table 1 summarises patients' characteristics. The main tumour types treated were: lung cancer (20 pts, 30%), cancer of an unknown primary (11 pts, 16%) and breast cancer (9 pts, 13%). There was an even distribution of male and female patients with a mean age of 57 years (range: 25–75). The patients were divided into four groups according to the main alopecia-causing drug: Group A, TX-based regimes (without ANR); Group B, TX+ANR; Group C, ANR-based regimes (without
Discussion
Alopecia is a distressing side-effect of chemotherapy, having a negative impact on the quality of life of most patients [24]. Several methods of preventing chemotherapy-induced alopecia have been used over the years. The most widely applied method is the cooling of the scalp by a variety of techniques ranging from ice packs applied to the entire scalp to more sophisticated methods which use cryogel caps with or without tourniquets or cold air 13, 20, 23, 25. These methods are based on the
Acknowledgements
The authors wish to express their gratitude to Medical Specialties of California UK for providing the Penguin Cold Caps used in this study and MSC Hellas A.E. who sponsored this study and the cold therapy nurses Maria Kravariti and Photini Masoura for their significant contribution to the success of cold therapy.
References (33)
- et al.
A randomised study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study
Ann. Oncol.
(1997) - et al.
Effectiveness of cold cap in the prevention of docetaxel-induced alopecia
Eur. J. Cancer
(1997) - et al.
Scalp cooling by thermocirculator
Lancet
(1982) - et al.
Scalp cooling has no place in the prevention of alopecia in adjuvant chemotherapy for breast cancer
Eur. J. Cancer
(1994) - et al.
Docetaxel-induced alopecia can be prevented
Lancet
(1995) - et al.
Effect of peri-operative chemotherapy on the quality of life of patients with early breast cancer
Eur. J. Cancer
(1990) - et al.
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer
J. Clin. Oncol.
(1998) - et al.
Dose and dose intensity of adjuvant chemotherapy for stage II, node positive breast carcinoma
N. Engl. J. Med.
(1994) - et al.
Randomised study of paclitaxel–cisplatin versus cisplatin–teniposide in patients with advanced non-small-cell lung cancer
J. Clin. Oncol.
(1998) - et al.
Long-term follow-up of patients with good-risk germ cell tumours treated with etoposide and cisplatin
J. Clin. Oncol.
(1997)